文献速递血管炎

巨细胞动脉炎中糖皮质激素的耐受性:一项患者报告不良事件的研究

Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究在一家三级中心向最近确诊为巨细胞动脉炎的100例患者发放问卷,回收分析90例,89例(99%)报告至少1种糖皮质激素相关不良事件(中位6种,范围1-11)。认知与心理改变(主要为失眠72%)影响90%患者,皮肤改变与肌肉减少影响70%患者且与身体自主功能受损相关(P=0.007);代谢问题影响49%患者。作者认为该真实世界研究提示随访中应仔细监测糖皮质激素相关不良事件,并鼓励对部分患者采用减少糖皮质激素用量的策略。

要点

  • 89例(99%)报告至少1种糖皮质激素相关不良事件,中位6种(范围1-11)。
  • 认知与心理改变影响90%患者,失眠占72%;皮肤改变与肌肉减少影响70%患者,与身体自主功能受损相关(P=0.007)。
  • 接受糖皮质激素超过18个月的患者中,视力问题(42%,P=0.01)与骨折(9%,P=0.007)报告更频繁。

核心结论

  • 该真实世界自评研究提供实用且更新的数据,提醒糖皮质激素耐受性仍比以往更值得关注。
  • 作者认为随访中应仔细监测糖皮质激素相关不良事件,并鼓励对部分患者采用减少糖皮质激素用量的策略。

研究设计与样本

  • 向一家三级中心最近确诊为巨细胞动脉炎的100例患者发放问卷,问卷包括关于疾病和糖皮质激素影响的开放式与封闭式问题。
  • 分析8个主要不良事件领域:心血管、代谢、肌肉、认知与心理、骨骼、皮肤与多毛、感染及视觉并发症;含衍生子项共18项糖皮质激素相关不良事件,分别分析并按糖皮质激素使用时长分析。
  • 共90例患者纳入分析。

主要发现

  • 89例(99%)报告至少1种糖皮质激素相关不良事件,中位6种(范围1-11)。
  • 认知与心理改变(主要为失眠72%)影响90%患者。
  • 皮肤改变与肌肉减少影响70%患者,与此事件相关的身体自主功能受损常见(P=0.007)。
  • 代谢问题(尤其是体重增加40%和糖尿病20%)影响49%患者。
  • 视力问题与骨折分别被42%和9%患者提及,在接受糖皮质激素超过18个月的患者中更频繁(分别为P=0.01和P=0.007)。

关键数值与推荐

  • 8个主要不良事件领域:心血管、代谢、肌肉、认知与心理、骨骼、皮肤与多毛、感染、视觉并发症。
  • 含衍生子项共18项糖皮质激素相关不良事件分别分析,并按糖皮质激素使用时长分析。

临床怎么用

  • 作者认为随访中应仔细监测糖皮质激素相关不良事件。
  • 作者鼓励对部分患者采用减少糖皮质激素用量的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess patients' self-reported glucocorticoid (GC)-related adverse events (AEs) in a GCA population. METHODS: A questionnaire was sent to the 100 patients most recently diagnosed with GCA in a tertiary centre. This questionnaire included open- and close-ended questions on the disease and GC effects. Eight primary AE areas were analysed: cardiovascular, metabolic, muscle, cognitive and psychologic, bone, cutaneous and hairiness, infective and visual complications. Including derivative subitems from preceding areas, a total of 18 GC-related AEs were analysed separately and according to GC duration. RESULTS: Ninety patients were analysed and 89 (99%) reported at least one GC-related AE [median 6 (range 1-11)]. Cognitive and psychological changes, primarily insomnia (72%), affected 90% of patients. Cutaneous changes and muscle loss affected 70% of patients, with frequent impairment of physical autonomy (P = 0.007) associated with this event. Metabolic issues, especially weight gain (40%) and diabetes mellitus (20%), affected 49% of patients. Conversely, vision troubles and bone fractures were mentioned by 42% and 9% of patients, respectively, and more frequently in patients who received GCs for >18 months (P = 0.01 and P = 0.007, respectively). Cardiovascular changes and infections affected 30% and 26% of patients, respectively. CONCLUSION: This real-life study of GC tolerance assessed using a self-evaluation provides pragmatic and updated data reminding us that GC tolerance remains more noteworthy than ever. This study suggests carefully monitoring GC-related AEs during follow-up and encourages GC-sparing strategies in some patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. de Boysson H, Barakat C, Dumont A, et al. Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events. Rheumatology (Oxford). 2022. PMID: 34919673. doi:10.1093/rheumatology/keab921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。